Prescription drug · ANDA
Doxazosin NDC 23155-095
Doxazosin mesylate 8 mg/1 · Tablet · Oral · Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 23155-095-01 | 23155009501 | 100 TABLET in 1 BOTTLE (23155-095-01)Marketed from Feb 13, 2018 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Doxazosin
- Generic name (nonproprietary)
- doxazosin
- Active ingredients
- Doxazosin mesylate — 8 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 205210
- Marketing start
- Listing expires
- Other FDA classes
- Adrenergic alpha-Antagonists (Mechanism)
- Identifiers
- Product ID 23155-095_cf1c14bc-a5cc-4800-9ec8-d5fbe267c43cSPL ID cf1c14bc-a5cc-4800-9ec8-d5fbe267c43cSPL set ID 7991373e-8a62-47f9-b4fb-90573485af4eRxCUI 197625, 197626, 197627, 197628UNII 86P6PQK0MU
- Pharmacologic class
- alpha-Adrenergic Blocker
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N423155009501followed by a unit qualifier and the quantityPackage 23155-0095-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Doxazosin is an alpha 1 adrenergic antagonist indicated for: Signs and symptoms of Benign Prostatic Hyperplasia (BPH) Treatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of…
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 205210
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Doxazosin | Doxazosin mesylate 4 mg/1 | TabletOral | Golden State Medical Supply, Inc. | 84677-046 |
| Doxazosin | Doxazosin mesylate 1 mg/1 | TabletOral | Golden State Medical Supply, Inc. | 84677-044 |
| Doxazosin | Doxazosin mesylate 2 mg/1 | TabletOral | Golden State Medical Supply, Inc. | 84677-045 |
| Doxazosin | Doxazosin mesylate 4 mg/1 | TabletOral | A-S Medication Solutions | 50090-8055 |
| Doxazosin | Doxazosin mesylate 8 mg/1 | TabletOral | Golden State Medical Supply, Inc. | 84677-047 |
| Doxazosin | Doxazosin mesylate 1 mg/1 | TabletOral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 23155-092 |
| Doxazosin | Doxazosin mesylate 2 mg/1 | TabletOral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 23155-093 |
| Doxazosin | Doxazosin mesylate 4 mg/1 | TabletOral | Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 23155-094 |